Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094413 | 1.00 | L3MBTL1 (0.55) | L3MBTL1BCHEKMT2AMEN1LMNA | |
| SCHEMBL6272264 | 1.00 | L3MBTL1 (0.55) | L3MBTL1BCHEKMT2AMEN1LMNA | |
| SCHEMBL6092690 | 0.91 | KMT2A (0.62) | L3MBTL1BCHEKMT2AMEN1LMNA | |
| SCHEMBL6095014 | 0.91 | KMT2A (0.62) | L3MBTL1BCHEKMT2AMEN1LMNA | |
| SCHEMBL6092685 | 0.91 | KMT2A (0.62) | L3MBTL1BCHEKMT2AMEN1LMNA | |
| SCHEMBL6093314 | 0.82 | OPRK1 (0.62) | L3MBTL1BCHEKMT2AMEN1LMNA | |
| SCHEMBL6093321 | 0.82 | OPRK1 (0.62) | L3MBTL1BCHEKMT2AMEN1LMNA | |
| SCHEMBL4814380 | 0.80 | L3MBTL1 (0.57) | L3MBTL1KMT2AMEN1LMNATP53 | |
| SCHEMBL6095234 | 0.79 | BCHE (0.50) | BCHEKMT2AMEN1ATMKDM4E | |
| SCHEMBL6095230 | 0.79 | BCHE (0.50) | BCHEKMT2AMEN1ATMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078565-B2 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2006-07-18 | — | — | US | disclosed |
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020584-A1 | Benzamide derivatives as antagonists of orexin receptors | HCRTR2, HCRTR1, OXTR | L3MBTL1 4080/4885BCHE 440/4885KMT2A 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.